Product Candidates Thrombotargets is developing a new and advanced generation of drugs, like TT-173 or TT-105. Product Candidates Therapeutic Focus
	TT-173 m The first antihemorrhagic drug useful for topically treating all kinds of bleeding: TT-173.  m Currently in pre clinical phase, it is expected to receive IND at Q1 2011. To date, this topical treatment for bleeding has received two Orphan Drug Designations from the FDA and it is projected as an alternative in new local haemostatic agent because of its advantages like: easy topical administration, broad therapeutic focus (deficits of FV,FVII, FVIII, FIX, FX, FXI and FXII, thrombocytopenias of diverse origin...), it is able to stop bleeding caused by heparin and warfarin treatment, exerts a potent acute effect and physiological fibrin clot formation.   TT-173 is a human recombinant hemostatic protein that has been designed to cover these unmet needs representing a novel and significantly radical approach for the topical treatment of bleeding disorders. TT-173 is intended to treat all kind of bleeding disorders in: Healthy subjects        Hemophilia A, B and C Factor VII deficiency Von Willebrand Disease Thrombocytopenias Congenital Platelet Disorders (i.e. Glanzmann's Disease, Bernard-Soulier Syndrome) Hemorrhages induced by anticoagulant and antiplatelet therapies Our internal studies have confirmed that TT-173 will be able to treat topical bleeding episodes in Haemophiliacs patients, even when a lethal haemorrhage is present. P TT-105 BioPlatformScreenTM has discovered a new anticoagulant agent through anunexplored target implicated in the coagulation pathway:  TT-105.   m The lead candidate, a monoclonal antibody, shows high potency, good selectivity and demonstrates high efficacy in ex vivo human experiments and in several in vivo animal models.  Thrombotargets is advancing this program towards the preclinical development and has started a new program to obtain an orally bio available small molecule.